Intercept's NASH drug is again rejected by FDA, leading the company to restructure in pivot from disease
Intercept Pharmaceuticals’ NASH drug obeticholic acid was rejected by the FDA for a second time on Thursday, and the company says it will now discontinue …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.